The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention

Suh, Jung–Won; Chung, Woo-Young; Kim, Yong-Seok; Kim, Kwang Il; Jeon, Eun-Ju; Cho, Young-Seok; Youn, Tae‐Jin; Chae, In‐Ho; Kim, Cheol-Ho; Choi, Dong‐Ju

doi:10.1016/j.ijcard.2010.02.002

Cited by 44 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statistical heterogeneity was negligible for these outcomes (I 2 =0%). Since MRI is currently considered to be the most objective method of assessment in patients with ischemic heart diseases [16], we therefore separately analyzed the four trials [5][6][7][8] that used MRI in assessing cardiac function. Again, no statistically significant improvement in LVEF was observed (WMD 1.16%; 95% CI −0.38 to 2.70%; p=0.14).…”

Section: Discussionmentioning

confidence: 99%

“…Among the remaining 16 RCTs, seven were ultimately excluded because they were duplicated reports or unfinished trials or they did not fulfill the inclusion criteria. The remaining nine RCTs [5][6][7][8][9][10][11][12][13] fulfilled our inclusion criteria and were included in this meta-analysis (Fig. 1).…”

Section: Selected Studies and Characteristicsmentioning

confidence: 99%

“…It has been suggested that drug treatments for acute myocardial infarction (AMI) that include erythropoiesis-stimulating agents (ESAs), such as recombinant human EPO and its analogue darbepoetin, may protect the affected myocardium, limit infarct size, and attenuate post-infarct remodeling when administered well after the onset of reperfusion [3,4]. Random control trials (RCTs) using either EPO or its analog darbepoetin [5][6][7][8][9][10][11][12][13] are currently underway to examine the clinical efficacy and safety of ESAs in patients with acute ST-segment elevation myocardial infarction (STEMI). Since the RCTs conducted to date have involved relatively limited sample sizes and have yielded heterogeneous results regarding to the effects of ESAs, we have performed a meta-analysis of results collected from clinical RCTs with the aim to explore the potential therapeutic effects and to assess the safety of EPO in the treatment of patients with acute STEMI.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review

Gao

et al. 2011

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Selected Studies and Characteristicsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review

Gao

et al. 2011

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Suh et al 67 reported a smaller negative trial of erythropoietin. A total of 57 patients with STEMI received intravenous bolus of recombinant human erythropoietin (50 U/kg) immediately before PCI or usual therapy.…”

Section: Other Older and Newer Pharmacological Approaches Erythropoietinmentioning

confidence: 99%

“…60,61 Large REVEAL study showed no reduction of infarct size 62,63 and several other recent trials were negative for infarct size reduction [64][65][66][67] Glucose-insulin-potassium Recent large IMMEDIATE trial assessed 12 h GIK infusion started out-of-hospital. No decrease in progression to enzymatic evidence of infarction.…”

Section: Erythropoietinmentioning

confidence: 99%

Current State of Clinical Translation of Cardioprotective Agents for Acute Myocardial Infarction

Kloner

2013

Circulation Research

138

112

View full text Add to dashboard Cite

Abstract:There is continued interest in the concept of limiting myocardial infarct size with adjunctive agents administered along with reperfusion injury; however, there remains considerable controversy in the literature. The purpose of this article is to review the medical literature on clinical trials performed during the past 3 years that have attempted to reduce myocardial infarct size by administration of adjunctive therapies along with reperfusion therapy. A PubMed-driven literature search revealed a host of clinical trials focusing on the following prominent types of therapies: endogenous conditioning (postconditioning and remote ischemic conditioning); rapid cooling; pharmacological therapy (cyclosporine, abciximab, clopidogrel, tirofiban, erythropoietin, thrombus aspiration, adenosine, glucose-insulin-potassium, statins, antidiabetic agents, FX06, iron chelation, and ranolazine). Although there remains some controversy, quite a few of these studies showed that adjunctive therapy further reduced myocardial infarct size when coupled with reperfusion. Antiplatelet agents are emerging as some of the newest agents that seem to have cardioprotective capabilities. Postconditioning has become a bit more controversial in the clinical literature; remote conditioning, early and rapid cooling, adenosine, and ranolazine are intriguing therapies deserving of larger studies. Certain agents and maneuvers, such as erythropoietin, protein kinase C δ inhibitors, iron chelation, and intra-aortic balloon counterpulsation, perhaps should be retired. The correct adjunctive therapy administered along with reperfusion has the capability of further reducing myocardial injury during ST-segment-elevation myocardial infarction. ( infarct size reducing agents in clinical trials. Some of these disappointing agents included antibodies that prevent white blood cell adhesion to the endothelium; eniporide, a sodium/hydrogen exchange inhibitor; caldaret, an intracellular calcium-handling modulator; nicorandil, a potassium ATP channel opener/vasodilator; glucose-insulin-potassium (GIK); delcasertib (a protein kinase C δ inhibitor); and erythropoietin. 5 However, some agents and maneuvers that were observed to work in experimental models did show promise in clinical trials of MI under the right circumstances: postconditioning; remote conditioning; cyclosporine (maintains the mitochondrial permeability transition pore closed); intravenous adenosine infusions; atrial natriuretic peptide; mild hypothermia induced before reperfusion; supersaturated oxygen therapy and others. [4][5][6][7] The reasons for discrepancies between experimental findings and clinical trials have been reviewed in detail. 6,7 Since these reviews were written there have been a large number of new clinical trials recently published during the past 3 years, on the basis of literature searches through PubMed. These trials cover additional new studies on therapies, such as conditioning, abciximab, clopidogrel, erythropoietin, hypothermia, thrombectomy, intracoronary adenosine...

show abstract

Harms of off-label erythropoiesis-stimulating agents for critically ill people

Mesgarpour

Heidinger

Roth

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Low quality of evidence suggests that off-label use of ESAs may reduce mortality in a critical care setting. There was a lack of high-quality evidence about the harm of ESAs in critically-ill people. The information for biosimilar ESAs is less conclusive. Most studies neither evaluated ESAs' harm as a primary outcome nor predefined adverse events. Any further studies of ESA should address the quality of evaluating, recording and reporting of adverse events.

show abstract

The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention

Cited by 44 publications

References 30 publications

Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review

Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review

Current State of Clinical Translation of Cardioprotective Agents for Acute Myocardial Infarction

Harms of off-label erythropoiesis-stimulating agents for critically ill people

Contact Info

Product

Resources

About